Medicare Enrolled

Dr. Anan Haija, M.D.

Rheumatology · Galloway, NJ
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
318 CHRIS GAUPP DR, Galloway, NJ 08205
6097487104
In practice since 2007 (19 years)
NPI: 1487869152 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Haija from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Haija? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Haija

Dr. Anan Haija is a rheumatology specialist in Galloway, NJ, with 19 years of NPI registration. Based on federal Medicare data, Dr. Haija performed 156,417 Medicare services across 843 unique beneficiaries.

Between the years covered by Open Payments, Dr. Haija received a total of $203,825 from 30 pharmaceutical and/or device companies across 886 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Haija is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 5% volume in NJ $203,825 industry payments

Medicare Practice Summary

Medicare Utilization ↗
156,417
Medicare services
Top 5% in NJ for rheumatology
843
Unique beneficiaries
$7
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~8,232 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Certolizumab injection (Cimzia)
An injection of certolizumab pegol administered under the direct supervision of a physician.
129,215 $4 $17
Golimumab infusion (Simponi Aria)
Administration of golimumab medication directly into a vein. This code specifies the dosage amount of 1 milligram for intravenous delivery.
15,855 $11 $36
Denosumab injection (Prolia/Xgeva) 4,565 $18 $45
Abatacept infusion (Orencia)
An injection of abatacept administered under the direct supervision of a physician. This code is used for Medicare when the drug is not self-administered.
4,404 $34 $125
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
959 $105 $235
Non-hormonal chemotherapy injection
This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue.
865 $63 $200
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
199 $113 $450
Injection, methylprednisolone acetate, 40 mg 154 $6 $13
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
93 $140 $340
Ultrasound-guided large joint aspiration or injection
This procedure uses ultrasound imaging to guide the removal of fluid from or the injection of medication into a large joint.
73 $110 $481
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
35 $74 $160
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
13.1% high complexity
86.2% medium
0.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$203,825
Total received (2018-2024)
Avg $29,118/year across 7 years
Top 5% in NJ for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
30
Companies
886
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$195,445 (95.9%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$6,955 (3.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$1,425 (0.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$21,288
2023
$37,304
2022
$38,610
2021
$18,133
2020
$26,901
2019
$37,585
2018
$24,004

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
ABBVIE INC.
$19,190
Amgen Inc.
$548
Janssen Biotech, Inc.
$355
AstraZeneca Pharmaceuticals LP
$264
Novartis Pharmaceuticals Corporation
$189
GlaxoSmithKline, LLC.
$186
UCB, Inc.
$135
Alexion Pharmaceuticals, Inc.
$100
ANI Pharmaceuticals, Inc.
$96
Lilly USA, LLC
$82
PFIZER INC.
$55
Aurinia Pharma U.S., Inc.
$33
Fresenius Kabi USA, LLC
$32
Fidia Pharma USA Inc.
$24
Top 3 companies account for 94.4% of 2024 payments
All-time payments by company (2018-2024) ›
ABBVIE INC.
$69,461
Novartis Pharmaceuticals Corporation
$33,413
Amgen Inc.
$28,548
AbbVie Inc.
$22,981
AbbVie, Inc.
$20,123
Celgene Corporation
$13,807
Aurinia Pharma U.S., Inc.
$7,089
Janssen Biotech, Inc.
$1,671
Novartis Pharma AG
$1,425
NOVARTIS PHARMACEUTICALS CORPORATION
$700
GlaxoSmithKline, LLC.
$665
Horizon Therapeutics plc
$656
AstraZeneca Pharmaceuticals LP
$630
UCB, Inc.
$610
Lilly USA, LLC
$511
Mallinckrodt Hospital Products Inc.
$327
ANI Pharmaceuticals, Inc.
$236
PFIZER INC.
$222
Exeltis, USA Inc.
$139
Genentech USA, Inc.
$122
Alexion Pharmaceuticals, Inc.
$114
GENZYME CORPORATION
$113
Boehringer Ingelheim Pharmaceuticals, Inc.
$82
E.R. Squibb & Sons, L.L.C.
$57
Fresenius Kabi USA, LLC
$32
Fidia Pharma USA Inc.
$24
Organon LLC
$20
Kowa Pharmaceuticals America, Inc.
$16
AMAG Pharmaceuticals, Inc.
$15
Avion Pharmaceuticals
$15
Top 3 companies account for 64.5% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · BENLYSTA · Bimzelx · COSENTYX · Cimzia · EVENITY · EVUSHELD · Enbrel · FERAHEME · FORTEO · Gloperba · HUMIRA · HYALGAN · Humira · IDACIO · JARDIANCE · KEVZARA · KRYSTEXXA · LUPKYNIS · ORENCIA · Otezla · PURIFIED CORTROPHIN GEL · Prolia · REMICADE · RENFLEXIS · RINVOQ · Rinvoq · Rituxan · SAPHNELO · SEGLENTIS · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · UPLIZNA · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (96%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 5% for rheumatology in NJ.

Looking for a rheumatology specialist in Galloway?
Compare rheumatologists in the Galloway area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
8
Per 100K population
2.9
County median income
$76,819
Nearest hospital
ATLANTICARE REGIONAL MEDICAL CENTER - CITY CAMPUS
7.2 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Haija is a mixed practice specialist, with above-average Medicare volume (top 5% in NJ), with speaking/promotional industry engagement in the top 5% of NJ peers, with 19 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Haija experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Haija performed 129,215 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Haija receive payments from pharmaceutical companies?
Yes. Dr. Haija received a total of $203,825 from 30 companies across 886 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Haija's costs compare to other rheumatologists in Galloway?
Dr. Haija's average Medicare payment per service is $7. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Haija) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →